Invitation to presentation of Xbrane Biopharma’s interim report January – March 2020 on May 13, 2020.

Corporate Information

English

News

Presentation

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on May 13, 2020, at 16.00 a.m. CET. Xbrane will publish the Company’s interim report January – March 2020, on Wednesday May 13, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the interim report January – March 2020, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): 08 002 796 619
Sweden (Local): +46 (0) 850 692 180
Sweden (Toll Free): 020 012 51 60
US (Local): +1 646 741 31 67
US (Toll Freee): +1 877 870 91 35
Confirmation Code: 18 56 899

Web link:
https://edge.media-server.com/mmc/p/aniha5nx

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane’s headquarter is located in Solna outside of Stockholm and the company’s in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.